Gedatolisib after CDK4/6 inhibition in HR-Positive/HER2-negative advanced breast cancer: pharmacology, phase iii evidence, and therapeutic positioning.

Authors

Aziz Ullah, Muhammad Saeed Akhtar

Published in

Expert opinion on pharmacotherapy. Oct 17, 2026. Epub Oct 17, 2026.

Abstract

Progression following CDK4/6 inhibition remains a therapeutic challenge in hormone receptor-positive, HER2-negative advanced breast cancer. Gedatolisib, an FDA-approved pan-class I PI3K/mTORC1/2 inhibitor, introduces a treatment strategy for disease without a detected PIK3CA mutation.
This review critically evaluates gedatolisib pharmacology, clinical evidence, safety, biomarkers, and therapeutic positioning. PubMed/MEDLINE, publisher platforms, ClinicalTrials.gov, regulatory sources, and oncology conference records were searched through July 2026, with updates through September 2026. In phase III VIKTORIA-1, median progression-free survival was 9.3 versus 2.0 months with gedatolisib-fulvestrant-palbociclib versus fulvestrant (hazard ratio 0.24) and 7.4 versus 2.0 months with gedatolisib-fulvestrant versus fulvestrant (hazard ratio 0.33). Experimental regimens were not directly compared in a powered analysis. Stomatitis, metabolic toxicity, palbociclib-associated neutropenia, and weekly intravenous administration complicate treatment delivery.
Gedatolisib expands post-CDK4/6 treatment options, but optimal positioning requires individualized patient selection without assuming triplet superiority. Mature survival outcomes, validated predictive biomarkers, comparative sequencing evidence, and VIKTORIA-2 findings will determine its long-term clinical value.

PMID:
42888943
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.